Skip to main content
. Author manuscript; available in PMC: 2011 Jul 1.
Published in final edited form as: J Neurochem. 2010 Apr 19;114(1):215–225. doi: 10.1111/j.1471-4159.2010.06760.x

Table 1.

Peptidomics results for PC1/3 null mice

Precursor Peptide name Upstream Sequence Downstream Theor
mass		 Obs
Mass		 ppm z #T Reg. PC1
Het/WT		 PC1 KO/WT
Avg SEM Avg SEM Sig n
7B2 200–212 .LDNVVAKK SVPHFSEEEKEAE * 1516.67 1516.71 25 3 2 Amy 1.12 0.20 1.40 0.12 3
7B2 200–212 .LDNVVAKK (SVPHFpSEEEKEAE) * 1596.63 1596.65 12 3 2 Amy 1.19 0.13 1.30 0.08 3
7B2 200–212 .LDNVVAKK (SVPHFpSEEEKEAE) * 1596.63 1596.62 −2 3 2 Stri 0.88 0.16 0.91 0.20 3
CART 82–86 .LKKLKSKR (IPIYE) KKYGQVPM. 633.33 633.32 16 1 1 Hyp 2.21 0.22 1.33 0.07 3
Chromogranin A 392–402 .MKLSFRTR AYGFRDPGPQL RRGWRPSS. 1219.60 1219.62 20 2 1 Hyp 1.67 0.07 1.48 0.13 3
Chromogranin B 438–446 .LDTREEKR LLDEGHYPV RESPIDTA. 1041.52 1041.53 10 2 1 Hyp 1.01 0.11 0.23 0.07 **a 3
Chromogranin B 438–446 .LDTREEKR LLDEGHYPV RESPIDTA. 1041.52 1041.50 −16 2 1 Stri 0.87 0.31 0.37 0.05 nsa, **b 3
Chromogranin B 588–597 .VNWGYEKR SFARAPQLDL KRQYDGVA. 1116.59 1116.60 11 2 1 Amy 1.05 0.10 1.25 0.09 3
Chromogranin B 588–597 .VNWGYEKR SFARAPQLDL KRQYDGVA. 1116.59 1116.62 26 2 1 Hyp 1.45 0.23 1.19 0.04 3
Chromogranin B 588–597 .VNWGYEKR SFARAPQLDL KRQYDGVA. 1116.59 1116.58 −6 2 1 Stri 0.95 0.23 0.90 0.08 3
Chromogranin B 438–454 .LDTREEKR LLDEGHYPVRESPIDTA KRYPQSKW. 1910.93 1910.96 14 3 1 Amy 1.10 0.13 1.48 0.23 3
Chromogranin B 438–454 .LDTREEKR LLDEGHYPVRESPIDTA KRYPQSKW. 1910.93 1911.02 48 3 1 Hyp 1.01 0.26 1.38 0.41 3
Chromogranin B 438–454 .LDTREEKR LLDEGHYPVRESPIDTA KRYPQSKW. 1910.93 1910.94 7 3 1 Stri 1.09 0.27 0.99 0.15 3
Chromogranin B 313–330 .HPLSEERR PSPKESKEADVATVRLGE KRSHHLAH. 1911.99 1911.97 −12 4 3 Amy 1.26 0.03 1.41 0.14 3
Chromogranin B Phosphorylated
357–373		 .GEESRSYR GLQYRGRGpSEEDRAPRP RSEESQER. 2022.97 2022.94 −15 4 1 Amy 0.86 0.01 0.36 0.09 **a 3
Chromogranin B Phosphorylated
357–374		 .GEESRSYR GLQYRGRGpSEEDRAPRPR SEESQERE. 2179.07 2179.05 −10 5 1 Amy 0.81 0.15 0.57 0.10 nsa, **b 3
Procholecystokinin 36–44 .ATDPVEQR (AQEAPRRQL) RAVLRTDG. 1067.58 1067.59 4 3 1 Stri 1.38 0.23 1.31 0.31 2
Proenkephalin Leu-Enkephalin .WWMDYQKR YGGFL KRFAESLP. 555.27 555.25 −38 1 1 Hyp 1.36 0.35 0.96 0.24 3
Proenkephalin Met-Enkephalin .GGEILAKR YGGFM KKDADEGD. 573.23 573.23 7 1 1 Amy 1.86 0.14 1.71 0.27 nsa, **b 3
Proenkephalin Met-Enkephalin .GGEILAKR YGGFM KKDADEGD. 573.23 573.20 −49 1 1 Hyp 1.37 0.41 0.98 0.36 3
Proenkephalin Met-Enkephalin .GGEILAKR YGGFM KKDADEGD. 573.23 573.23 −1 1 1 Stri 0.99 0.32 0.90 0.33 3
Proenkephalin Octapeptide .NDEDMSKR YGGFMRSL KRSPQLED. 929.45 929.47 22 2 1 Hyp 1.39 0.24 1.84 0.36 3
Proenkephalin Octapeptide .NDEDMSKR YGGFMRSL KRSPQLED. 929.45 929.42 −29 2 1 Stri 1.02 0.27 1.15 0.23 3
Proenkephalin 197–208 .GFMRSLKR SPQLEDEAKELQ KRYGGFMR. 1385.67 1385.67 −1 3 2 Amy 1.97 0.19 2.32 0.39 nsa, **b 3
Proenkephalin 197–208 .GFMRSLKR SPQLEDEAKELQ KRYGGFMR. 1385.67 1385.68 9 2 2 Hyp 1.56 0.77 0.78 0.22 nsa 2
Proenkephalin 197–208 .GFMRSLKR SPQLEDEAKELQ KRYGGFMR. 1385.67 1385.66 −2 3 2 Stri 1.07 0.18 1.08 0.27 3
Prohormone
convertase 1		 619–628 . NTVQNDRR GVEKMVNVVE KRPTQKSL. 1102.57 1102.53 −33 2 2 Hyp 0.53 0.19 <0.10 **a 3
Promelanin
concentrating
hormone		 Neuropeptide EI .AESTQEKR EIGDEENSAKFPI-amide GRRDFDML. 1446.68 1446.71 15 3 2 Amy 1.20 0.07 1.58 0.28 nsa, **b 3
Promelanin
concentrating
hormone		 Neuropeptide EI .AESTQEKR EIGDEENSAKFPI-amide GRRDFDML. 1446.68 1446.68 −5 2 2 Hyp 1.31 0.04 1.54 0.41 nsa,b 3
Promelanin
concentrating
hormone		 Neuropeptide EI .AESTQEKR EIGDEENSAKFPI-amide GRRDFDML. 1446.68 1446.72 23 2 2 Stri 1.08 0.22 0.69 0.04 nsa, **b 3
Proneurotensin Neuromedin N .EKEEVIKR KIPYIL KRQLYENK. 745.47 745.44 −39 2 2 Hyp 1.15 0.19 0.93 0.17 3
Proneurotensin Neurotensin .KIPYILKR pELYENKPRRPYIL KRGSYYY* 1671.91 1671.93 12 3 1 Hyp 0.98 0.19 0.72 0.13 2
ProPACAP 111–128 .YLQSVVAR GAGENLGGSAVDDPAPLT KRHSDGIF. 1639.77 1639.83 35 2 1 Hyp 1.06 0.15 0.87 0.16 3
ProSAAS KEP 1–7 signal peptide (ARPVKEP) RSLSAASA. 795.46 795.44 25 3 2 Hyp 1.36 0.05 0.73 0.07 **a 3
ProSAAS KEP signal peptide (ARPVKEPR) SLSAASAP. 951.56 951.55 −7 3 2 Hyp 1.44 0.18 0.80 0.07 **a 3
ProSAAS Little LEN .GALLRVKR LENPSPQAPA RRLLPP* 1022.50 1022.51 12 2 1 Amy 1.15 0.01 0.45 0.02 **a 3
ProSAAS Little LEN .GALLRVKR LENPSPQAPA RRLLPP* 1022.50 1022.52 20 2 1 Hyp 1.29 0.16 0.31 0.08 *a 2
ProSAAS Little LEN .GALLRVKR LENPSPQAPA RRLLPP* 1022.50 1022.51 7 2 1 Stri 0.90 0.19 0.34 0.11 *a 3
ProSAAS Little SAAS 5–16 .KEPRSLSA ASAPLVETSTPL RLRRAVPR. 1184.63 1184.64 6 2 1 Hyp 1.37 0.10 0.90 0.17 2
ProSAAS Little SAAS 1–16 ARPVKEPR SLSAASAPLVETSTPL RLRRAVPR. 1542.81 1542.82 6 2 1 Amy 1.25 0.11 1.08 0.13 3
ProSAAS Little SAAS 1–16 ARPVKEPR SLSAASAPLVETSTPL RLRRAVPR. 1542.81 1542.85 24 2 1 Hyp 1.53 0.34 0.82 0.19 3
ProSAAS Little SAAS 1–16 ARPVKEPR SLSAASAPLVETSTPL RLRRAVPR. 1542.81 1542.81 −3 2 1 Stri 1.10 0.26 0.59 0.09 nsa,b 3
ProSAAS Big LEN .GALLRVKR LENPSPQAPARRLLPP * 1754.98 1754.99 4 3 1 Amy 1.50 0.13 2.44 0.10 **a 3
ProSAAS Big LEN .GALLRVKR LENPSPQAPARRLLPP * 1754.98 1755.02 25 3 1 Hyp 1.76 0.30 2.70 0.45 nsa, **b 3
ProSAAS Big LEN .GALLRVKR LENPSPQAPARRLLPP * 1754.98 1754.99 6 3 1 Stri 1.12 0.17 1.06 0.08 3
ProSAAS Little SAAS ARPVKEPR SLSAASAPLVETSTPLRL RRAVPRGE. 1812.01 1812.04 21 3 1 Hyp 1.32 0.15 0.70 0.10 *a 3
ProSAAS Big SAAS 1–24 signal peptide ARPVKEPRSLSAASAPLV ETSTPL RLRRAVPR. 2476.37 2476.41 18 4 2 Hyp 1.95 0.55 5.00 1.00 nsa, **b 2
Prosomatostatin Somatostatin 28–14 .EMRLELQR SANSNPAMAPRE RKAGCKNF. 1243.56 1243.57 9 2 1 Amy 1.01 0.04 0.32 0.02 **a 3
Prosomatostatin Somatostatin 28–14 w/ MetOx .EMRLELQR (SANSNPAMoxAPRE) RKAGCKNF. 1259.56 1259.58 12 2 1 Amy 1.12 0.13 0.24 0.02 **a 3
Prosomatostatin Somatostatin 28–14 w/ MetOx .EMRLELQR (SANSNPAMoxAPRE) RKAGCKNF. 1259.56 1259.55 −9 2 1 Stri 0.80 0.14 0.21 0.01 *a 2
ProVasoactive
Intestinal Peptide		 111–122 .LESLIGKR ISSSISEDPVPI KRHSDAVF. 1242.63 1242.63 1 2 1 Stri 0.67 0.67 1
Provasopressin 154-end .LLLRLVQL AGTRESVDSAKPRVY * 1634.84 1634.85 10 4 2 Hyp 1.22 2.33 1
Provasopressin 151-end .ARALLLRL VQLAGTRESVDSAKPRVY * 1975.05 1975.10 28 4 2 Hyp 0.70 2.10 1
Secretogranin III 23–36 signal peptide FPKPEGSQDKSLHN RELSAERP. 1582.77 1582.78 6 4 3 Amy 1.14 0.12 0.57 0.05 **a 3
Secretogranin III 23–36 signal peptide FPKPEGSQDKSLHN RELSAERP. 1582.77 1582.76 −7 4 3 Hyp 1.38 0.25 <0.20 **a 3
VGF 489–507 .EEKRKRKK NAPPEPVPPPRAAPAPTHV RSPQPPPP. 1914.01 1914.01 1 3 1 Amy 0.94 0.12 0.88 0.08 3
VGF 489–507 .EEKRKRKK NAPPEPVPPPRAAPAPTHV RSPQPPPP. 1914.01 1913.99 −10 3 1 Stri 0.94 0.11 0.55 0.06 *a 3

Precursor and peptide names are indicated in columns 1 and 2. Amino acid sequences around the cleavage the cleavage sites are indicated in column 3 (upstream) and column 5 (downstream). Most peptide sequences listed in column 4 were derived from MS/MS sequence information, in addition to several other criteria (mass within 0.005% of a known peptide, and the correct number of isotopic tags incorporated and charge state based on amino acid composition; see Materials and Methods) . However, for some peptides there was insufficient MS/MS information and these peptides are therefore only tentatively identified by the matches to known peptides; these tentatively identified peptides are indicated by parentheses surrounding the sequence. Abbreviations: Theor. Mass, theoretical monoisotopic mass in Da; Obs Mass, the observed monoisotopic molecular mass (in Da) of the unprotonated peptide after subtracting mass of tags; ppm, the difference in parts per million between the observed and theoretical masses; z, charge state;

#

T, number of TMAB labels observed on the peptides; Reg., brain region where the peptides was found: Amy, Amygdala; Hyp, Hypothalamus; and Stri, Striatum. PC1 Het/WT ratio, the ratio of peptide levels in extracts of PC1/3 heterozygous brain regions relative to the levels in extracts of wild-type mice. PC1 KO/WT ratio, the ratio of peptide levels in extracts of PC1/3 null brain regions relative to the levels in extracts of wild-type mice. Avg.and SEM indicate the average and standard error of the mean of ratios among the runs in which peptides were found. Sig., level of significance of PC1 KO/WT compared to PC1 Het/WT or wild-type/wild-type ratios: ns, not significant;

*

p ≤0.05;

**

p ≤0.01;

a

statistical significance versus PC1 Het/WT ratios;

b

statistical significance versus wild-type/wild-type ratios previously published (Zhang et al. 2008). n, number of runs in which the peptide was found. Note: SAAS, and VGF are not abbreviations; these are peptide names. CART, cocaine- and amphetamine-regulated transcript; PACAP, pituitary adenylate cyclase-activating polypeptide. Mox, or MetOx, oxidized methionine. pS, phosophoserine.

HHS Vulnerability Disclosure